lgml
posit
viral
rp
result
antibiot
administ
patient
within
first
h
antibiot
discontinu
within
h
laboratori
result
avail
conclus
result
suggest
posit
viral
rp
low
pct
result
infrequ
associ
discontinu
antibiot
therapi
proven
possibl
respiratori
infect
institut
direct
intervent
clinician
like
need
correct
behavior
decreas
unnecessari
antibiot
use
result
patient
pct
andor
rp
result
includ
pct
rp
test
obtain
patient
respect
patient
result
test
suggest
patient
potenti
candid
antibiot
avoid
includ
introduct
pneumonia
remain
among
top
common
caus
mortal
age
group
unit
state
common
infecti
caus
mortal
unit
state
pneumonia
respons
million
hospit
admiss
death
pneumonia
commonli
caus
viral
bacteri
pathogen
former
respons
case
clinic
sign
symptom
associ
two
etiolog
often
indistinguish
despit
advanc
clinic
applic
diagnost
technolog
report
mani
patient
nonetheless
continu
receiv
antibiot
therapi
without
regard
posit
viral
pcr
andor
low
pct
result
object
determin
frequenc
chang
empir
antibiot
therapi
known
proven
case
pneumonia
result
respiratori
panel
rp
andor
pct
test
known
clinician
thu
determin
need
activ
stewardship
intervent
institut
retrospect
singlecent
studi
addit
patient
copd
chronic
bronchiti
emphysema
exclud
lack
util
pct
distinguish
viral
bacteri
respiratori
ill
copd
describ
basic
studydesign
flow
illustr
fig
procalcitonin
concentr
determin
vida
brahm
pct
autom
test
marci
franc
pct
report
sensit
specif
distinguish
bacteri
infect
inflammatori
process
routin
laboratori
report
denot
valu
individu
patient
record
pct
andor
rp
result
met
inclus
studi
fig
lgml
posit
pcr
tabl
median
durat
antibiot
day
outpati
set
includ
emerg
depart
major
antibiot
prescrib
patient
present
respiratori
condit
mani
infect
viral
origin
includ
nearli
pneumonia
turn
much
antibiot
prescrib
respiratori
infect
outpati
unwarr
unnecessari
antibiot
use
hospit
patient
appar
respiratori
tract
infect
also
occur
overus
explain
larg
extent
inher
difficulti
clinic
differenti
bacteri
viral
infect
time
appear
treatment
respiratori
tract
infect
repres
major
area
opportun
judici
limit
use
antibiot
util
rapid
diagnost
test
may
help
differenti
use
pct
rp
alon
combin
success
safe
use
guid
diagnosi
therapi
number
studi
shown
pct
effect
test
util
alter
antibiot
prescrib
pattern
without
advers
affect
patient
outcom
studi
empir
antibiot
therapi
strongli
iqr
interquartil
rang
pct
procalcitonin
rp
respiratori
panel
antibiot
durat
inform
made
avail
primari
care
provid
patient
posit
viral
rp
disclos
primari
care
provid
n
median
durat
antibiot
day
oppos
day
p
patient
proven
bacteri
infect
n
furthermor
posit
viral
pcr
disclos
n
median
durat
antibiot
dayssimilar
bacteri
infect
group
find
decreas
antibiot
exposur
base
viral
pcr
also
report
oosterheert
colleagu
studi
posit
pr
result
led
discontinu
antibiot
patient
one
potenti
challeng
relianc
rapid
test
rule
bacteri
infect
coinfect
viral
bacteri
pathogen
report
studi
clinicianprescrib
behavior
institut
rp
andor
pct
laboratori
result
avail
prescrib
physician
suggest
pure
viral
respiratori
infect
observ
antibiot
discontinu
rate
patient
posit
viral
rp
result
lgml
patient
test
result
avail
n
highli
suggest
pure
viral
infect
antibiot
discontinu
rate
even
lower
one
possibl
explan
low
rate
antibiot
discontinu
could
relat
rel
low
prescrib
antibiot
patient
proven
suspect
respiratori
infect
either
low
pct
posit
viral
rp
result
believ
rel
low
incid
prescrib
context
suggest
mani
prescrib
avoid
antibiot
therapi
base
clinic
factor
suggest
nonbacteri
ill
caus
respiratori
symptom
earlier
studi
falsey
colleagu
respiratori
ill
reflect
similar
result
substanti
opportun
judici
antimicrobi
use
base
result
rp
pct
singlecent
studi
patient
deem
pure
viral
infect
viral
test
posit
bacteri
test
neg
serum
pct
level
lgml
admiss
day
two
hospit
durat
inpati
antibiot
found
significantli
less
viral
alon
group
compar
mix
viralbacteri
group
mean
vs
day
respect
data
suggest
opportun
use
combin
rp
pct
result
narrow
etiolog
diagnosi
perhap
decreas
unnecessari
antibiot
exposur
mix
viralbacteri
infect
note
patient
util
diagnost
batteri
appear
distinguish
pure
viral
infect
also
notabl
howev
rp
pct
result
suggest
pure
viral
infect
result
shorter
durat
antibiot
therapi
averag
durat
therapi
extend
day
beyond
avail
result
rp
pct
test
recent
followup
studi
antibiot
prescrib
pattern
associ
low
pct
posit
viral
rp
result
patient
nonpneumon
lower
respiratori
tract
infect
character
two
group
patient
one
receiv
standard
care
second
receiv
care
specifi
use
pct
algorithm
viral
test
investig
observ
antibiot
discontinu
rate
pct
lgml
posit
viral
rp
report
substanti
differ
antibiot
discontinu
rate
observ
sever
differ
studi
method
like
explain
dispar
result
importantli
nonpneumon
appar
defin
clinic
suggest
symptom
lower
respiratori
tract
infect
clear
evid
risk
factor
bacteri
pneumonia
previou
studi
conduct
institut
recent
studi
method
result
studi
share
medic
staff
prior
commenc
proactiv
intervent
provid
asp
import
ensur
meaning
use
rapid
diagnost
oppos
lack
clinic
benefit
absenc
aspfacilit
intervent
